
## Anna Kruczak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/621504/publications.pdf Version: 2024-02-01



ANNA KOUCZAK

#	Article	IF	CITATIONS
1	Prognostic Evaluation of Proliferative Activity and DNA Content in the Phyllodes Tumor of the Breast: Immunohistochemical and Flow Cytometric Study of 118 Cases. Breast Cancer Research and Treatment, 2001, 65, 77-85.	2.5	80
2	Prognostic evaluation of cutaneous malignant melanoma: A clinicopathologic and immunohistochemical study. , 1999, 70, 150-160.		55
3	Metallothionein-3 Increases Triple-Negative Breast Cancer Cell Invasiveness via Induction of Metalloproteinase Expression. PLoS ONE, 2015, 10, e0124865.	2.5	30
4	Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. Polish Journal of Pathology, 2015, 2, 133-141.	0.3	25
5	Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. Genome Research, 2015, 25, 1521-1535.	5.5	25
6	Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma. Polish Journal of Pathology, 2012, 3, 179-183.	0.3	22
7	Relationship between <em>HER2</em> gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment. OncoTargets and Therapy, 2018, Volume 11, 4525-4535.	2.0	21
8	Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting. Journal of Cancer, 2017, 8, 131-139.	2.5	16
9	Prognostic and predictive significance of p53, ECFr, Ki-67 in larynx preservation treatment. Reports of Practical Oncology and Radiotherapy, 2010, 15, 87-92.	0.6	10
10	Prognostic potential of topoisomerase $ll\hat{l}\pm$ and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. Breast, 2011, 20, 338-350.	2.2	9
11	Application of high-resolution genomic profiling in the differential diagnosis of liposarcoma. Molecular Cytogenetics, 2017, 10, 7.	0.9	6
12	Metaplastic breast cancer with rapidly progressive recurrence in a young woman: case report and review of the literature. Archives of Medical Science, 2016, 6, 1384-1388.	0.9	5
13	Podoplanin-positive Cancer-associated Stromal Fibroblasts in Primary Tumor and Synchronous Lymph Node Metastases of HER2-overexpressing Breast Carcinomas. Anticancer Research, 2018, 38, 1957-1965.	1.1	5
14	The role of histology, grading, location of tumour and ploidy in evaluation of outcome in patients with liposarcoma. Polish Journal of Pathology, 2017, 68, 343-351.	0.3	1
15	High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma. Polish Journal of Pathology, 2020, 71, 107-119.	0.3	1
16	Histopathological assessment of residual retroperitoneal mass removed in patients after chemotherapy for non-seminomatous germ cell tumours of the testis. Polish Journal of Pathology, 2015, 4, 420-425.	0.3	0